{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T18:53:00Z","timestamp":1770231180914,"version":"3.49.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>Immune checkpoints are critical for the regulation of tumor growth and regression. Recently an effect of CD80 and CD86 on tumor regression in canine cutaneous histiocytoma has been described. Further, the expression of MX dynamin like GTPase 1 (mx1) in cancer is linked to immune evasion. Thus, the present study aimed to investigate the effects of CD80 and CD86 in histiocytic sarcoma (HS), a rare and progressive malignancy in dogs and to elucidate the status of the interferon-I pathway. Twenty-two tissue samples of HS from skin, lung and liver of 15 dogs were used. Immunohistochemistry targeting CD80, CD86, programmed death-ligand 1 (PD-L1), survivin, cleaved caspase-3 (Casp-3), stimulator of interferon genes (STING) and mx1 was performed. Slides were digitized and analyzed with QuPath. The numbers of CD86- and Casp-3 expressing cells showed a positive correlation. In the skin and lung, numbers of CD80 immunolabeled cells were higher than for CD86, while CD80 and CD86 levels were comparable in the liver. In general, low numbers of PD-L1 immunolabeled tumor cells were detected. Intranuclear survivin expression was linked to Casp-3. Mx1 and STING were expressed in tumor cells. A possible link between CD86 and Casp-3 points to a role of CD86 in tumor cell death. The findings indicate relevant differences in CD80 and CD86 expression between organs and a function in histiocytic disease in dogs. Further, the expression of markers of the interferon-type-I pathway indicates a role in immune evasion.<\/jats:p>","DOI":"10.3389\/fvets.2025.1546047","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:22:18Z","timestamp":1744176138000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["CD86 is linked to apoptosis in canine histiocytic sarcoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Benjamin","family":"Diehl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kirchhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Hansmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/0300985813510413","article-title":"A review of histiocytic diseases of dogs and cats","volume":"51","author":"Moore","year":"2014","journal-title":"Vet Pathol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1354\/vp.39-1-74","article-title":"Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs","volume":"39","author":"Affolter","year":"2002","journal-title":"Vet Pathol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e0302231","DOI":"10.1371\/journal.pone.0302231","article-title":"Incidence rates of the most common canine tumors based on data from the Swiss Canine Cancer Registry (2008 to 2020)","volume":"19","author":"Dhein","year":"2024","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1111\/vco.12252","article-title":"Clinical prognostic factors in canine histiocytic sarcoma","volume":"15","author":"Dervisis","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1365-3164.2007.00615.x","article-title":"Cutaneous reactive histiocytosis in dogs: a retrospective evaluation of 32 cases","volume":"18","author":"Palmeiro","year":"2007","journal-title":"Vet Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/00000372-200002000-00009","article-title":"Canine cutaneous and systemic histiocytosis: reactive histiocytosis of dermal dendritic cells","volume":"22","author":"Affolter","year":"2000","journal-title":"Am J Dermatopathol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jcpa.2022.07.009","article-title":"Tumour incidence in dogs in Germany: a retrospective analysis of 109,616 histopathological diagnoses (2014\u20132019)","volume":"198","author":"Aupperle-Lellbach","year":"2022","journal-title":"J Comp Pathol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1354\/vp.43-5-632","article-title":"Canine hemophagocytic histiocytic sarcoma: a proliferative disorder of CD11d+ macrophages","volume":"43","author":"Moore","year":"2006","journal-title":"Vet Pathol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.immuni.2024.01.013","article-title":"The B7: CD28 family and friends: unraveling coinhibitory interactions","volume":"57","author":"Burke","year":"2024","journal-title":"Immunity"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s10875-010-9447-9","article-title":"Characterization of canine dendritic cells in healthy, atopic, and non-allergic inflamed skin","volume":"30","author":"Ricklin","year":"2010","journal-title":"J Clin Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1371931","DOI":"10.3389\/fvets.2024.1371931","article-title":"Immune checkpoint regulation is critically involved in canine cutaneous histiocytoma regression","volume":"11","author":"Diehl","year":"2024","journal-title":"Front Vet Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e18444","DOI":"10.7717\/peerj.18444","article-title":"Immuno-oncologic profiling by stage-dependent transcriptome and proteome analyses of spontaneously regressing canine cutaneous histiocytoma","volume":"12","author":"Loriani Fard","year":"2024","journal-title":"PeerJ"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/0300985820960131","article-title":"FoxP3, CTLA-4, and IDO in canine melanocytic tumors","volume":"58","author":"Porcellato","year":"2021","journal-title":"Vet Pathol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"110142","DOI":"10.1016\/j.vetimm.2020.110142","article-title":"Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours","volume":"230","author":"Ariyarathna","year":"2020","journal-title":"Vet Immunol Immunopathol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1033704","DOI":"10.3389\/fonc.2022.1033704","article-title":"Canine oral squamous cell carcinoma as a spontaneous, translational model for radiation and immunology research","volume":"12","author":"Boss","year":"2022","journal-title":"Front Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/j.1939-165X.2012.00449.x","article-title":"Multifocal cutaneous histiocytic sarcoma in a young dog and review of histiocytic cell immunophenotyping","volume":"41","author":"Mastrorilli","year":"2012","journal-title":"Vet Clin Pathol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.vetimm.2014.11.006","article-title":"Passage-dependent morphological and phenotypical changes of a canine histiocytic sarcoma cell line (DH82 cells)","volume":"163","author":"Heinrich","year":"2015","journal-title":"Vet Immunol Immunopathol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e0150030","DOI":"10.1371\/journal.pone.0150030","article-title":"Evaluation of costimulatory molecules in peripheral blood lymphocytes of canine patients with histiocytic sarcoma","volume":"11","author":"Tagawa","year":"2016","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3390\/vetsci8070120","article-title":"Prognostic value of PD-L1, PD-1 and CD8A in canine diffuse large B-cell lymphoma detected by RNAscope","volume":"8","author":"Aresu","year":"2021","journal-title":"Vet Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41698-021-00147-6","article-title":"PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma","volume":"5","author":"Maekawa","year":"2021","journal-title":"npj Precis Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"785","DOI":"10.3390\/cancers13040785","article-title":"Cross-reactivity and functionality of approved human immune checkpoint blockers in dogs","volume":"13","author":"Pantelyushin","year":"2021","journal-title":"Cancers"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.semradonc.2019.12.009","article-title":"Type I interferon response in radiation-induced anti-tumor immunity","volume":"30","author":"Zhang","year":"2020","journal-title":"Semin Radiat Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.trecan.2022.09.003","article-title":"How cancer cells make and respond to interferon-I","volume":"9","author":"Cheon","year":"2023","journal-title":"Trends Cancer"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12943-019-1087-y","article-title":"STING: a master regulator in the cancer-immunity cycle","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol Cancer"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1997385","DOI":"10.1080\/2162402X.2021.1997385","article-title":"Cancer-specific type-I interferon receptor signaling promotes cancer stemness and effector CD8+ T-cell exhaustion","volume":"10","author":"Gong","year":"2021","journal-title":"Onco Targets Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1038\/emboj.2013.203","article-title":"IFN\u03b2-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage","volume":"32","author":"Cheon","year":"2013","journal-title":"EMBO J"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e0150030","DOI":"10.1002\/ijc.28929","article-title":"Quantitative proteome profiling of lymph node-positive vs. -negative colorectal carcinomas pinpoints MX1 as a marker for lymph node metastasis","volume":"135","author":"Croner","year":"2014","journal-title":"Int J Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10549-020-05646-x","article-title":"Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer","volume":"181","author":"Aljohani","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.meegid.2013.02.010","article-title":"The myxovirus resistance A (MxA) gene-88GT single nucleotide polymorphism is associated with prostate cancer","volume":"16","author":"Glymph","year":"2013","journal-title":"Infect Genet Evol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"ref31","article-title":"RStudio: Integrated development for R","year":"2025"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"key":"ref33","article-title":"R: A language and environment for statistical computing","year":"2025"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S1471-4906(03)00111-X","article-title":"What\u2019s the difference between CD80 and CD86?","volume":"24","author":"Sansom","year":"2003","journal-title":"Trends Immunol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41590-022-01289-w","article-title":"Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation","volume":"23","author":"Kennedy","year":"2022","journal-title":"Nat Immunol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1177\/0300985817690208","article-title":"T lymphocytes in histiocytic sarcomas of Flat-Coated Retriever Dogs","volume":"54","author":"Marcinowska","year":"2017","journal-title":"Vet Pathol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-019-02189-8","article-title":"Tumor microenvironment differences between primary tumor and brain metastases","volume":"18","author":"Cacho-D\u00edaz","year":"2020","journal-title":"J Transl Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/vco.12197","article-title":"Immune regulation of canine tumour and macrophage PD-L1 expression","volume":"15","author":"Hartley","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"110560","DOI":"10.1016\/j.vetimm.2023.110560","article-title":"Characterization of expression and prognostic implications of transforming growth factor beta, programmed death-ligand 1, and T regulatory cells in canine histiocytic sarcoma","volume":"257","author":"Murphy","year":"2023","journal-title":"Vet Immunol Immunopathol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e0157176","DOI":"10.1371\/journal.pone.0157176","article-title":"Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma","volume":"11","author":"Maekawa","year":"2016","journal-title":"PLoS One"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2021.03.208","article-title":"How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy","volume":"32","author":"Fundytus","year":"2021","journal-title":"Ann Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"18311","DOI":"10.1038\/s41598-020-75533-4","article-title":"A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs","volume":"10","author":"Igase","year":"2020","journal-title":"Sci Rep"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2004638","DOI":"10.1080\/19420862.2021.2004638","article-title":"Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors","volume":"13","author":"Mason","year":"2021","journal-title":"MAbs"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"e79810","DOI":"10.1371\/journal.pone.0079810","article-title":"Inhibition of survivin influences the biological activities of canine histiocytic sarcoma cell lines","volume":"8","author":"Yamazaki","year":"2013","journal-title":"PLoS One"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/sj.cdd.4401091","article-title":"Differential subcellular localization of functionally divergent survivin splice variants","volume":"9","author":"Mahotka","year":"2002","journal-title":"Cell Death Differ"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"jcs223826","DOI":"10.1242\/jcs.223826","article-title":"Survivin at a glance","volume":"132","author":"Wheatley","year":"2019","journal-title":"J Cell Sci"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1096\/fj.06-5741com","article-title":"Nuclear export is essential for the tumor-promoting activity of survivin","volume":"21","author":"Knauer","year":"2007","journal-title":"FASEB J"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.canlet.2013.06.007","article-title":"Clinico-pathologic relevance of Survivin splice variant expression in cancer","volume":"339","author":"de Necochea-Campion","year":"2013","journal-title":"Cancer Lett"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2025.1546047\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:22:19Z","timestamp":1744176139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2025.1546047\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":50,"alternative-id":["10.3389\/fvets.2025.1546047"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2025.1546047","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"article-number":"1546047"}}